^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MCLA-129

i
Other names: MCLA-129, MCLA129, MCLA 129
Company:
Betta Pharma, Merus
Drug class:
EGFR inhibitor, c-MET inhibitor
Related drugs:
3ms
METex14: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination (clinicaltrials.gov)
P1/2, N=576, Recruiting, Merus N.V. | N=380 --> 576 | Trial completion date: Apr 2025 --> Mar 2027 | Trial primary completion date: Apr 2024 --> Mar 2026
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
Tagrisso (osimertinib) • MCLA-129
1year
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC) (ESMO Asia 2023)
Pts received a median of 2 lines of prior systemic therapy, including anti-PD-(L)1 (78%) and platinum-based chemotherapy (89%); 28% received cetuximab in the RM setting. No cases of interstitial lung disease were reported in this cohort. Conclusions MCLA-129 monotherapy demonstrated antitumor activity in pts with pretreated RM HNSCC with a manageable safety profile.
Clinical
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • MET expression
|
Erbitux (cetuximab) • MCLA-129
1year
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC) (ESMO Asia 2023)
Conclusions MCLA-129 plus osimertinib showed promising clinical efficacy in EGFRmut NSCLC, in 1L and 2L+. IRRs and ILD/pneumonitis were observed.
Clinical
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR expression • MET expression
|
Tagrisso (osimertinib) • MCLA-129
1year
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
MCLA-129 • Semena (befotertinib)
over1year
Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab (AACR 2023)
A phase 1/2 clinical trial of MCLA-129 in solid tumors is ongoing. These data support the further clinical development of MCLA-129 in patients with NSCLC and other solid tumors.
Preclinical • Tumor cell
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • MET exon 14 mutation • MET mutation
|
Rybrevant (amivantamab-vmjw) • MCLA-129 • onartuzumab (RG3638)
almost2years
Enrollment change • Metastases
|
IL6 (Interleukin 6) • IL2 (Interleukin 2)
|
Tagrisso (osimertinib) • MCLA-129
2years
MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study (AACR-NCI-EORTC 2022)
At the data cut-off date of 8 May 2022, 20 pts were enrolled, across the 100, 300, 600, 1000 and 1500 mg cohorts. Median age was 65.5 years (range 43-79). Pts enrolled included: 14 pts with EGFR mutant (mt) NSCLC (4 pts L858R, 8 pts Del19, 1 pt exon 20 insertion , 1 pt with other mutation), 2 pts with c-MET exon 14 mt NSCLC, 1 pt with c-MET amplified gastric adenocarcinoma , 1 pt with squamous esophageal cancer , and 2 pts with HNSCC.
Clinical • P1/2 data
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • MET amplification • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation
|
MCLA-129
over2years
Mechanism of action of MCLA-129, a bispecific antibody that targets EGFR and c-MET and impairs growth of EGFR exon 20 insertion mutant non-small cell lung cancer (AACR 2022)
Mutagenesis analysis identified critical binding residues of domain III of EGFR for MCLA-129 binding that are distinct from cetuximab binding. MCLA-129 is a Biclonics® common light chain bispecific antibody with multiple mechanisms of action including potent inhibition of c-MET and EGFR ligand binding, ligand-induced receptor dimerization and phosphorylation, ADCC and ADCP. MCLA-129 demonstrates significant growth inhibition of a patient-derived EGFR exon20ins tumor in a preclinical xenograft model. A phase 1/2 clinical trial of MCLA-129 in solid tumors is ongoing.
EGFR exon 20
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Erbitux (cetuximab) • MCLA-129
almost3years
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors (clinicaltrials.gov)
P1/2, N=400, Recruiting, Betta Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
MET positive
|
MCLA-129
over3years
New P1/2 trial
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR amplification • EGFR exon 20 insertion • MET exon 14 mutation • EGFR C797S • MET mutation • EGFR exon 20 mutation
|
FoundationOne® CDx
|
MCLA-129
over3years
Clinical • New P1/2 trial
|
EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
MET positive
|
MCLA-129
over3years
Clinical • New P1/2 trial
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL1B (Interleukin 1, beta)
|
MCLA-129
over3years
[VIRTUAL] Preclinical Evaluation of MCLA-129: A Bispecific Antibody Targeting c-MET and EGFR (PEGS 2021)
MCLA-129 is glycoengineered to enhance its Fc mediated ADCC and ADCP activity, thus allowing it to inhibit tumor growth independent of EGFR or c-MET signaling. MCLA-129 holds promise as a potential treatment option for NSCLC and other solid tumors.
Preclinical
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MCLA-129